Literature DB >> 31332514

More opioids, more constipation? Evaluation of longitudinal total oral opioid consumption and self-reported constipation in patients with cancer.

Eric J Roeland1, Christopher J Sera2, Joseph D Ma3.   

Abstract

PURPOSE: Opioid-induced constipation (OIC) is a distressing physical symptom for patients with cancer taking opioids. Total opioid consumption may contribute to developing worsening OIC-related symptoms. We completed a retrospective analysis examining the association of total daily opioid consumption on self-reported constipation in patients with cancer.
METHODS: In over 5 clinic visits, we collected self-reported constipation scores and 24-h oral morphine equivalents (OME). We examined the association between OME and the presence of constipation (i.e., score > 3) and the relationship of OME between patients with or without constipation.
RESULTS: Of 297 patients with cancer, we observed 57.8% with constipation and 42.4% without constipation at the first clinic visit. Age was similar in both groups (54.2 ± 14.5 vs. 56.4 ± 14.8 years [mean ± SD]) and the majority of patients were women (63.7% vs. 61.1%). The most common cancer type in patients with constipation was non-colorectal gastrointestinal (n = 25, 14.6%), while in patients without constipation was colorectal gastrointestinal (n = 25; 19.8%). Across visits, we observed weak or no association between OME and self-reported constipation (r = 0.01-0.27). At the first visit, higher mean OME was seen in patients who self-reported constipation (133.4 vs 76; p < 0.05). Age, sex, metastatic disease, and stimulant laxative use were not associated with constipation.
CONCLUSIONS: We observed weak to no association between OME and constipation in patients with cancer. These results suggest a lack of a clear association between total opioid consumption and self-reported constipation.

Entities:  

Keywords:  Constipation; Opioid; Opioid-induced constipation; Oral morphine equivalent; Stimulant laxative

Mesh:

Substances:

Year:  2019        PMID: 31332514     DOI: 10.1007/s00520-019-04996-7

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  18 in total

1.  Calculating opioid dose conversions #36.

Authors:  Robert Arnold; David E Weissman
Journal:  J Palliat Med       Date:  2003-08       Impact factor: 2.947

Review 2.  5-HT(3)-receptor antagonists for the treatment of nausea and vomiting: a reappraisal of their side-effect profile.

Authors:  Susan Goodin; Regina Cunningham
Journal:  Oncologist       Date:  2002

Review 3.  Opioid-induced constipation: advances and clinical guidance.

Authors:  Alfred D Nelson; Michael Camilleri
Journal:  Ther Adv Chronic Dis       Date:  2016-01-25       Impact factor: 5.091

Review 4.  Opioid-Induced Constipation.

Authors:  Lynn R Webster
Journal:  Pain Med       Date:  2015-10       Impact factor: 3.750

Review 5.  Opioids in chronic non-cancer pain: systematic review of efficacy and safety.

Authors:  Eija Kalso; Jayne E Edwards; Andrew R Moore; Henry J McQuay
Journal:  Pain       Date:  2004-12       Impact factor: 6.961

6.  Self-reported constipation in patients with advanced cancer: a preliminary report.

Authors:  Wadih Rhondali; Linh Nguyen; Lynn Palmer; Duck-Hee Kang; David Hui; Eduardo Bruera
Journal:  J Pain Symptom Manage       Date:  2012-07-25       Impact factor: 3.612

7.  Prevalence and impact of constipation and bowel dysfunction induced by strong opioids: a cross-sectional survey of 520 patients with cancer pain: DYONISOS study.

Authors:  L Abramowitz; N Béziaud; L Labreze; V Giardina; C Caussé; B Chuberre; F A Allaert; S Perrot
Journal:  J Med Econ       Date:  2013-10-25       Impact factor: 2.448

Review 8.  Management of opioid-induced constipation.

Authors:  D M Thorpe
Journal:  Curr Pain Headache Rep       Date:  2001-06

9.  Clinical evaluation of the efficacy of methylnaltrexone in resolving constipation induced by different opioid subtypes combined with laboratory analysis of immunomodulatory and antiangiogenic effects of methylnaltrexone.

Authors:  Elisabeth Cw Neefjes; Maurice Jdl van der Vorst; Manon Sa Boddaert; Wouter Wa Zuurmond; Hans J van der Vliet; Aart Beeker; Hendrik P van den Berg; Cornelis J van Groeningen; Suzan Vrijaldenhoven; Henk Mw Verheul
Journal:  BMC Palliat Care       Date:  2014-08-20       Impact factor: 3.234

Review 10.  Chronic constipation: A review of literature.

Authors:  Mojgan Forootan; Nazila Bagheri; Mohammad Darvishi
Journal:  Medicine (Baltimore)       Date:  2018-05       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.